Reported Saturday, Gilead And Merck's Islatravir-Lenacapavir Combo Demonstrates High Efficacy In Weekly HIV Treatment At Week 48 In Phase 2 Study
Portfolio Pulse from Benzinga Newsdesk
Gilead and Merck's investigational HIV treatment, a combination of Islatravir and Lenacapavir, shows high efficacy in a Phase 2 study, maintaining viral suppression in 94.2% of participants at 48 weeks.
October 21, 2024 | 7:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's Islatravir-Lenacapavir combo shows high efficacy in HIV treatment, maintaining 94.2% viral suppression at 48 weeks in Phase 2 study.
The positive results from the Phase 2 study of the Islatravir-Lenacapavir combo are likely to boost investor confidence in Gilead's HIV treatment pipeline, potentially leading to a positive short-term impact on GILD's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Merck's collaboration with Gilead on the Islatravir-Lenacapavir combo shows high efficacy in HIV treatment, maintaining 94.2% viral suppression at 48 weeks in Phase 2 study.
The successful results from the Phase 2 study of the Islatravir-Lenacapavir combo are likely to enhance Merck's reputation in HIV treatment, potentially leading to a positive short-term impact on MRK's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80